

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/645,967	08/24/2000	Wu Yang	393 A US	3909
75	90 03/12/2003			
David L Berstein ARIAD Gene Therapeutics Inc 26 Landsdowne Street			EXAMINER	
			KIFLE, BRUCK	
Cambridge, MA 02139-4234			ART UNIT	PAPER NUMBER
			1624	
			DATE MAILED: 03/12/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No. 09/645,967

Bruck Kifle, Ph.D.

Applicant(s)

Examiner

Art Unit

1624

Yang et al.



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED Mar 4, 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid the abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance: (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. THE PERIOD FOR REPLY [check only a) or b)] a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). A Notice of Appeal was filed on ______. Appellant's Brief must be filed within the 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 1. 🗆 . Appellant's Brief must be filed within the period set forth in 2. The proposed amendment(s) will not be entered because: (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below); (b) they raise the issue of new matter (see NOTE below); (c) X they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: see attached. 3. Applicant's reply has overcome the following rejection(s): 4. 🗆 would be allowable if submitted in Newly proposed or amended claim(s) a separate, timely filed amendment canceling the non-allowable claim(s). The a) affidavit, b) a exhibit, or c) a request for reconsideration has been considered but does NOT place the application in condition for allowance because: 6. 🗆 The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection. 7. 🗆 For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration: The proposed drawing correction filed on ______ is a) approved or b) disapproved by the Examines 8. 🗆 9. 🗆 Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). 10. Other: PRIMARY EXAMINER

ART UNIT 1624

Application/Control Number: 09/645,967 Page 2

Art Unit: 1624

Advisory Action

Claims 42-45 would be considered and claims 46-77 would still remain withdrawn.

Claims 1-41 would still be rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- i) The substituents on R²⁸ and R⁴³ (also R^A and R^B) are still not known. The "acyl" group still remain open-ended.
- ii) The definitions of heteroaliphatic, aryl and heteroaryl are not consistent with what is commonly known. There are no 3, 4, 5, 7, etc. aryl groups. A heteroaryl necessarily requires the presence of a heteroatom. A moiety having 3-14 carbon atoms can never be considered as a heteroaryl. The metes and bounds of heteroaliphatic is unknown.
- iii) The rejection over a pharmaceutically acceptable ester, carbamate, metabolite or prodrug or salt of such ester or carbamate remains.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

March 11, 2003

Bruck Kifle Primary Examiner Art Unit 1624